Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 2/20 | 0.37 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.37 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 4/20 | 0.33 |
| ▸ | AR | P10275 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17554936 | 0.91 | AKR1C3 (0.36) | AKR1C3AKR1C2NPBWR1MAPTAR | |
| SCHEMBL2103328 | 0.88 | AKR1C3 (0.38) | AKR1C3AKR1C2NPBWR1KDM4EMAPT | |
| SCHEMBL2107205 | 0.87 | AKR1C3 (0.37) | AKR1C3AKR1C2NPBWR1KDM4EMAPT | |
| SCHEMBL17554995 | 0.86 | AKR1C3 (0.34) | AKR1C3AKR1C2NPBWR1MAPTAR | |
| SCHEMBL17554900 | 0.82 | ALDH1A1 (0.36) | AKR1C3AKR1C2MAPTARALDH1A1 | |
| SCHEMBL2105478 | 0.80 | KIF11 (0.34) | — | |
| SCHEMBL17554823 | 0.78 | AKR1C3 (0.36) | AKR1C3AKR1C2NPBWR1MAPTAR | |
| SCHEMBL17554983 | 0.77 | ALDH1A1 (0.34) | AKR1C3AKR1C2MAPTARALDH1A1 | |
| SCHEMBL17554988 | 0.75 | PDE7A (0.37) | AKR1C3AKR1C2NPBWR1MAPTALDH1A1 | |
| SCHEMBL17554837 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163804-B2 | Composition for preventing harmful organisms | MITSUI CHEMICALS, INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090162453-A1 | COMPOSITION FOR PREVENTING HARMFUL ORGANISMS | MITSUI CHEMICALS, INC (JP) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090162453-A1 | COMPOSITION FOR PREVENTING HARMFUL ORGANISMS | PRDX3, CYP1A1, GSTA1 | AKR1C3 68/4885AKR1C2 259/4885NPBWR1 3239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.